To the Editor Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, has transformed the treatment landscape through ECHELON trials, including ECHELON-1 in previously untreated advanced-stage classical Hodgkin lymphoma (cHL) [1], ECHELON-2 in peripheral T-cell lymphoma (PTCL) [2], and ECHELON-3 in relapsed...
Ming-Ci Cai, O. Bai, Hui-Lai Zhang et al.· Blood Cancer Journal· 0 citations
Genomic instability and immune escape are linked features of hematologic malignancies, but the mechanisms that allow malignant cells to tolerate persistent nuclear and genotoxic stress while avoiding damaging DNA-sensing responses remain incompletely defined. Barrier-to-autointegration factor 1 (BANF1) is a small DNA-b...
Xia Jiang, Yi-Han Zhang, Dong Chen et al.· Frontiers in Immunology· 0 citations
G protein-coupled receptor 183 (GPR183; also known as EBI2, Epstein-Barr virus-induced G-protein-coupled receptor 2) has emerged as a central regulator linking 7α,25-dihydroxycholesterol (7α,25-OHC) gradients to immune cell trafficking and tissue organization. In this review, we synthesize the structural, physiological...
Hai-Hui Zhuang, Feng-Lin Li, Shuang-Yue Li et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
